L. Salvatore

FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study

AtezoTRIBE (NCT03721653) is a phase II randomized trial in which unresectable mCRC pts were randomized 1:2 to 1st-line FOLFOXIRI/bev [arm A] or FOLFOXIRI/bev/atezo [arm B]. Adding atezo t...

S. Tamberi ;

M. Bensi ;

I. Toma ;

M. De Grandis ;

M. Palermo ;

A. Cappetta ;

Sara Lonardi ;

A. Catteau ;

C. Antoniotti ;

L. Boni ;

F. Marmorino ;

J. Galon ;

V. Conca ;

R. Moretto ;

Filippo Pietrantonio ;

C. Cremolini ;

A. Passardi ;

M. Ambrosini ;

L. Salvatore ;

06/25/2023

Background The AtezoTRIBE study demonstrated that the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab prolongs PFS of mCRC patients, but a clinically modest benefit was obse...

Kirk McGregor ;

F. Bergamo ;

S. Leonetti ;

L. Provenzano ;

S. Tamberi ;

M. Ramundo ;

Giampaolo Tortora ;

C. Antoniotti ;

C. Rasola ;

A. Boccaccino ;

D. Ross ;

V. Conca ;